This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Patient Safety/ Medical Error  • Psoriasis  • Drug Therapy  • Alert me on articles by topic

Sustained Efficacy and Safety of Adalimumab in Psoriasis Treatment: A Retrospective Study of 49 Patients With and Without a History of TNF- Antagonist Treatment

Livia Van, MD; Sapna V. Modi, MD; Deborah J. Yang, MD; Sylvia Hsu, MD

Arch Dermatol. 2008;144(6):804-806.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Of the 3 available tumor necrosis factor (TNF-) antagonists, infliximab and etanercept are approved for treatment of moderate to severe, chronic, plaque-type psoriasis.^1-2 Although no standardized comparison trial exists, infliximab appears to be the most rapidly effective, but this initial efficacy is often eventually lost with the development of human antichimeric antibodies in 15% to 69% of patients.^1-3

Adalimumab, the third TNF- antagonist, is currently in phase III trials for psoriasis treatment. As a fully human IgG1 monoclonal antibody, it is expected to have less immunogenicity and secondary antibody-mediated loss of efficacy.^1-2 Despite clinical reports of antiadalimumab antibodies, impact on long-term clinical response is unclear.⁴

One recent study demonstrated adalimumab to be efficacious for psoriasis treatment of patients with no previous exposure to TNF antagonists.⁵ Since it is uncertain whether long-term response to adalimumab (. . . [Full Text of this Article]

Methods


Results

Comment
Efficacy

Safety

Conclusion

AUTHOR INFORMATION